These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 35581938)

  • 1. Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo.
    Gorsuch CL; Nemec P; Yu M; Xu S; Han D; Smith J; Lape J; van Buuren N; Ramirez R; Muench RC; Holdorf MM; Feierbach B; Falls G; Holt J; Shoop W; Sevigny E; Karriker F; Brown RV; Joshi A; Goodwin T; Tam YK; Lin PJC; Semple SC; Leatherbury N; Delaney Iv WE; Jantz D; Rhoden Smith A
    Mol Ther; 2022 Sep; 30(9):2909-2922. PubMed ID: 35581938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
    Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
    J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Mouse Model Harboring Hepatitis B Virus Covalently Closed Circular DNA.
    Xu Z; Zhao L; Zhong Y; Zhu C; Zhao K; Teng Y; Cheng X; Chen Q; Xia Y
    Cell Mol Gastroenterol Hepatol; 2022; 13(4):1001-1017. PubMed ID: 34896285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.
    Testoni B; Lebossé F; Scholtes C; Berby F; Miaglia C; Subic M; Loglio A; Facchetti F; Lampertico P; Levrero M; Zoulim F
    J Hepatol; 2019 Apr; 70(4):615-625. PubMed ID: 30529504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel recombinant cccDNA-based mouse model with long term maintenance of rcccDNA and antigenemia.
    Wu M; Wang C; Shi B; Fang Z; Qin B; Zhou X; Zhang X; Yuan Z
    Antiviral Res; 2020 Aug; 180():104826. PubMed ID: 32502604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment.
    Ruan P; Zhou B; Dai X; Sun Z; Guo X; Huang J; Gong Z
    Mol Med Rep; 2014 Apr; 9(4):1135-41. PubMed ID: 24566465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models.
    Yi J; Lei X; Guo F; Chen Q; Chen X; Zhao K; Zhu C; Cheng X; Lin J; Yin H; Xia Y
    Antiviral Res; 2023 Jul; 215():105618. PubMed ID: 37142191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector.
    Lucifora J; Salvetti A; Marniquet X; Mailly L; Testoni B; Fusil F; Inchauspé A; Michelet M; Michel ML; Levrero M; Cortez P; Baumert TF; Cosset FL; Challier C; Zoulim F; Durantel D
    Antiviral Res; 2017 Sep; 145():14-19. PubMed ID: 28709657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B Virus Core Protein Is Not Required for Covalently Closed Circular DNA Transcriptional Regulation.
    Zhong Y; Wu C; Xu Z; Teng Y; Zhao L; Zhao K; Wang J; Wang W; Zhan Q; Zhu C; Chen X; Liang K; Cheng X; Xia Y
    J Virol; 2022 Nov; 96(21):e0136222. PubMed ID: 36226986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intramolecular recombination enables the formation of hepatitis B virus (HBV) cccDNA in mice after HBV genome transfer using recombinant AAV vectors.
    Ko C; Su J; Festag J; Bester R; Kosinska AD; Protzer U
    Antiviral Res; 2021 Oct; 194():105140. PubMed ID: 34284057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
    Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
    J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential.
    Xia Y; Guo H
    Antiviral Res; 2020 Aug; 180():104824. PubMed ID: 32450266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregenomic RNA Launch Hepatitis B Virus Replication System Facilitates the Mechanistic Study of Antiviral Agents and Drug-Resistant Variants on Covalently Closed Circular DNA Synthesis.
    Zhao Q; Chang J; Rijnbrand R; Lam AM; Sofia MJ; Cuconati A; Guo JT
    J Virol; 2022 Dec; 96(24):e0115022. PubMed ID: 36448800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA.
    Zhuang AQ; Chen Y; Chen SM; Liu WC; Li Y; Zhang WJ; Wu YH
    Viruses; 2023 Nov; 15(12):. PubMed ID: 38140556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients.
    Wang Y; Liu Y; Liao H; Deng Z; Bian D; Ren Y; Yu G; Jiang Y; Bai L; Liu S; Liu M; Zhou L; Chen Y; Chen X; Duan Z; Lu F; Zheng S
    Int J Med Sci; 2022; 19(5):858-866. PubMed ID: 35693741
    [No Abstract]   [Full Text] [Related]  

  • 17. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B].
    Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg-positive patients with functional cure following PEG-IFN-based therapy.
    Gao N; Guan G; Xu G; Wu H; Xie C; Mo Z; Deng H; Xiao S; Deng Z; Peng L; Lu F; Zhao Q; Gao Z
    Aliment Pharmacol Ther; 2023 Nov; 58(10):1086-1098. PubMed ID: 37644711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment.
    Grudda T; Hwang HS; Taddese M; Quinn J; Sulkowski MS; Sterling RK; Balagopal A; Thio CL
    J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 35797115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA.
    Wong DK; Seto WK; Cheung KS; Chong CK; Huang FY; Fung J; Lai CL; Yuen MF
    Liver Int; 2017 Jul; 37(7):995-1001. PubMed ID: 27992681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.